Berberine for NAFLD: What the Randomized Trials Show on Liver Enzymes and Steatosis

← Back to articles

Berberine is an isoquinoline alkaloid best known for lowering blood glucose, where pooled data place its effect roughly in the range of low-dose oral agents. Its use in non-alcoholic fatty liver disease (NAFLD, now often relabelled metabolic dysfunction-associated steatotic liver disease) is a logical extension: the disease is tightly linked to insulin resistance, and most fatty-liver drug development targets the same metabolic machinery. The evidence in NAFLD specifically is smaller and noisier than the headline "berberine for diabetes" literature, so it is worth separating what the randomized trials actually measured from what gets claimed for it.

Why berberine is studied in fatty liver

Fatty liver is, at its core, a problem of where the body stores excess energy. Insulin resistance pushes fat into the liver, and the same metabolic dysfunction drives the type 2 diabetes and dyslipidemia that usually travel with it. Berberine's documented actions on glucose and lipid handling — partly via activation of the cellular energy sensor AMP-activated protein kinase — are therefore aimed squarely at the upstream drivers of the disease, which is why researchers have tested it here. That also means most of its apparent liver benefit may be indirect, downstream of better metabolic control rather than a direct effect on liver tissue.

What the pooled trials show

The most directly relevant synthesis is a 2024 systematic review and meta-analysis of berberine in NAFLD that pooled 10 randomized controlled trials in 811 patients [1]. Berberine produced statistically significant reductions in the three liver enzymes that track hepatocyte stress: alanine aminotransferase (ALT, standardized mean difference −0.72, 95% CI −1.01 to −0.44), aspartate aminotransferase (AST, SMD −0.79) and gamma-glutamyl transpeptidase (GGT, SMD −0.62). It also improved triglycerides, total and LDL cholesterol, and insulin resistance measured by HOMA-IR, while body-mass index fell modestly. A standardized mean difference near −0.7 is a moderate effect, but because the trials reported enzymes in different units it is hard to translate into a single "X units of ALT" figure — and the analysis flagged meaningful heterogeneity between studies.

Imaging endpoints are where the evidence thins. Most trials in the pooled analyses tracked blood markers rather than directly quantifying liver fat. A separate 2024 network meta-analysis of seven plant compounds in NAFLD ranked berberine behind artichoke leaf extract and naringenin for enzyme and lipid endpoints, which is a useful reminder that "significant in a meta-analysis" does not mean "best in class" [2].

The individual trials are small and mixed

Pooled effects can mask how heterogeneous the underlying studies are. In an open-label Chinese trial, 184 patients randomized to lifestyle intervention, lifestyle plus pioglitazone, or lifestyle plus berberine 0.5 g three times daily for 16 weeks; the berberine arm cut MRI-measured hepatic fat content from about 53% to 36%, more than lifestyle alone, with parallel weight and lipid improvement [3]. By contrast, a randomized trial in 50 Iranian patients found berberine had no significant effect on liver enzymes, lipids or fasting glucose versus control [4]. A 2024 double-blind, placebo-controlled trial in 70 patients (1.5 g/day for 12 weeks) landed in between: ALT and total cholesterol improved significantly, but most other lipid and glucose measures did not [5]. The most rigorous fatty-liver trial used a berberine–ursodeoxycholate salt rather than plain berberine — a phase 2 placebo-controlled study in 100 patients with presumed steatohepatitis and diabetes met its primary endpoint, cutting liver fat by 4.8% versus 2.0% on placebo, but that is a distinct drug candidate, not the supplement sold over the counter [6].

What the evidence does not establish

No published trial of berberine has biopsy-confirmed improvement in steatohepatitis or fibrosis, and none reports hard outcomes such as progression to cirrhosis. Follow-up rarely exceeds 16–24 weeks, samples are small, and many trials are open-label with unclear risk of bias. The honest summary is that berberine reliably nudges liver enzymes and the metabolic markers upstream of fatty liver, but whether that translates into less liver disease over years is untested. Weight loss of 7–10% remains the only intervention with histological evidence behind it, and the FDA-approved agent for biopsy-confirmed steatohepatitis with fibrosis, resmetirom, has not been compared head-to-head with berberine.

Dose, form and safety

Berberine has very low oral bioavailability — under 1% as the parent compound — because of P-glycoprotein efflux and extensive first-pass metabolism [7]. That is why the studied dose is split, typically 500 mg three times daily for about 1.5 g total. Dihydroberberine, a reduced form, is marketed as better absorbed, but it has not been tested head-to-head against standard berberine for fatty-liver endpoints, so any absorption advantage is theoretical for this use.

On safety, gastrointestinal complaints (diarrhea, cramping, constipation) are the most common adverse events and are usually mild and dose-related [3][6]. Berberine inhibits the drug-metabolizing enzyme CYP3A4 and the P-glycoprotein transporter, which can raise blood levels of co-administered medications such as statins, cyclosporine and some others, so anyone on prescription drugs should check for interactions. Berberine-containing herbs were historically restricted in some countries over concern that berberine can displace bilirubin and aggravate jaundice in newborns, particularly those with G6PD deficiency; a clinical review judged ordinary oral use to be safe in adults while still cautioning against use in pregnancy and breastfeeding [8]. Given the absence of pregnancy safety data, berberine should be avoided by anyone who is pregnant or nursing.

Sources

1. Nie Q, Li M, Huang C, et al. "The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review." Journal of Translational Medicine, 2024;22(1):225. PMID 38429794.
2. Liu H, Li Y, Jin Y, et al. "Effects of different natural products in patients with non-alcoholic fatty liver disease—A network meta-analysis of randomized controlled trials." Phytotherapy Research, 2024;38(7):3801-3824. PMID 38886838.
3. Yan HM, Xia MF, Wang Y, et al. "Efficacy of berberine in patients with non-alcoholic fatty liver disease." PLoS One, 2015;10(8):e0134172. PMID 26252777.
4. Nejati L, Movahedi A, Salari G, et al. "The effect of berberine on lipid profile, liver enzymes, and fasting blood glucose in patients with non-alcoholic fatty liver disease (NAFLD): a randomized controlled trial." Medical Journal of the Islamic Republic of Iran, 2022;36:39. PMID 36128280.
5. Koperska A, Moszak M, Seraszek-Jaros A, et al. "Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial." Journal of Physiology and Pharmacology, 2024;75(3). PMID 39042390.
6. Harrison SA, Gunn N, Neff GW, et al. "A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes." Nature Communications, 2021;12(1):5503. PMID 34535644.
7. Kong Y, Yang H, Nie R, et al. "Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence." European Journal of Medical Research, 2025;30(1):477. PMID 40506769.
8. Linn YC, Lu J, Lim LC, et al. "Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases." Phytotherapy Research, 2012;26(5):682-686. PMID 22002596.